Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in NASH
NCT02469272Phase 1Unknown
- Sponsor
- Lifespan Biotech
- Start
- May 2015
- Primary completion
- Jun 2018
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in Nonalcoholic steatohepatitis (NASH), sponsored by Lifespan Biotech. Primary endpoint: degree of hepatic steatosis as determined by MRI at 12 weeks. Status: unknown.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02469272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02469272.